TY - CHAP
T1 - Esophageal Cancers
T2 - Leveraging Alterations in Mitochondrial Biology to Improve Patient Outcomes
AU - Kabir, Mohammad Faujul
AU - Murray, Mary Grace
AU - Saxena, Reshu
AU - Klochkova, Alena
AU - Cruz, Jasmine
AU - Whelan, Kelly A.
N1 - Publisher Copyright:
© 2022 Elsevier Inc. All rights reserved
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Esophageal cancer is one of the most aggressive forms of human malignancy. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the predominant histological subtypes of esophageal cancer. Although ESCC and EAC differ with regard to pathophysiology, histology, geographical distribution, risk factors, and clinical characteristics, both have 5-year survival rates of less than 20%, underscoring the need for a better understanding of esophageal cancer biology in order to improve patient outcomes in this disease. Mitochondria are dynamic organelles that play essential roles in various cellular processes, including metabolism, redox homeostasis, calcium signaling, and apoptosis. As such, it is not surprising that alterations in mitochondrial biology have been associated with carcinogenesis across tissue types. Here, we will review the current literature implicating mitochondria in the development and progression of esophageal cancer, both ESCC and EAC, as well as how mitochondrial biology may intersect with therapeutic response in these deadly malignancies. Given the urgent need for effective strategies to improve patient outcomes in esophageal cancer, critical examination of mitochondrial biology in the context of ESCC and EAC has great potential to provide insights that will guide development of novel approaches to diagnosis, monitoring, and therapy for these deadly disease entities.
AB - Esophageal cancer is one of the most aggressive forms of human malignancy. Esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) are the predominant histological subtypes of esophageal cancer. Although ESCC and EAC differ with regard to pathophysiology, histology, geographical distribution, risk factors, and clinical characteristics, both have 5-year survival rates of less than 20%, underscoring the need for a better understanding of esophageal cancer biology in order to improve patient outcomes in this disease. Mitochondria are dynamic organelles that play essential roles in various cellular processes, including metabolism, redox homeostasis, calcium signaling, and apoptosis. As such, it is not surprising that alterations in mitochondrial biology have been associated with carcinogenesis across tissue types. Here, we will review the current literature implicating mitochondria in the development and progression of esophageal cancer, both ESCC and EAC, as well as how mitochondrial biology may intersect with therapeutic response in these deadly malignancies. Given the urgent need for effective strategies to improve patient outcomes in esophageal cancer, critical examination of mitochondrial biology in the context of ESCC and EAC has great potential to provide insights that will guide development of novel approaches to diagnosis, monitoring, and therapy for these deadly disease entities.
KW - Cancer therapy
KW - Esophageal cancer
KW - Mitochondria
UR - http://www.scopus.com/inward/record.url?scp=85151193375&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-820472-6.00074-8
DO - 10.1016/B978-0-12-820472-6.00074-8
M3 - Chapter
AN - SCOPUS:85151193375
VL - 6
SP - 96
EP - 111
BT - Comprehensive Pharmacology
PB - Elsevier
ER -